Drug Profile
Research programme: wnt signalling pathway inhibitors - Biosplice Therapeutics
Alternative Names: Research programme: wnt signalling pathway inhibitors - EpitherixLatest Information Update: 19 Apr 2021
Price :
$50
*
At a glance
- Originator Epitherix
- Developer Biosplice Therapeutics
- Class Small molecules
- Mechanism of Action Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 15 Apr 2021 Samumed is now called Biosplice Therapeutics
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 03 Apr 2014 This programme is still in active development